Shop compounds

Multi-receptor agonist peptide investigated for simultaneous GLP-1, GIP, and glucagon receptor engagement.

Stabilized GHRH(1-44) analog investigated for GHRH receptor activation and extended metabolic stability.

Mitochondria-derived peptide investigated for AMPK pathway activation and metabolic regulation.

Copper-binding tripeptide investigated for procollagen expression and extracellular matrix remodeling signaling.

Four-peptide tissue-research blend extending Glow with KPV - investigated across cell and matrix biology models for angiogenesis, extracellular matrix remodeling, and NF-κB pathway modulation.

Combined formulation for multi-compound tissue research designs investigating complementary matrix signaling pathways.

Central coenzyme investigated for roles in cellular energy metabolism, sirtuin activation, and DNA repair pathways.

ACTH(4-10) analog investigated for neurotrophic activity via BDNF and NGF expression.

Pentadecapeptide investigated for cytoprotective properties and nitric oxide system modulation in connective tissue models.

Alpha-MSH tripeptide fragment investigated for NF-κB pathway modulation and cytokine transcript signaling.

Thymosin beta-4 fragment studied for actin-binding properties and roles in cell migration and angiogenesis signaling.

Two-compound blend pairing the GHRH analog CJC-1295 (No-DAC) with the selective GHS-R1a agonist Ipamorelin - investigated for complementary receptor signaling in pharmacology research.

Glucagon-like peptide-2 investigated for GLP-2 receptor activation and intestinal epithelial proliferation signaling.

Endogenous thiol tripeptide investigated for redox homeostasis and Phase II conjugation pathway activity.

Selective GHS-R1a agonist studied for receptor subtype selectivity against cortisol and prolactin pathways.

GHRH(1-29) amide analog investigated for GHRH receptor activation on pituitary somatotrophs.

Tetrapeptide investigated for telomerase activation via hTERT expression in cellular senescence models.

Three-peptide tissue-research blend pairing GHK-Cu, BPC-157, and TB-500 - investigated across cell and matrix biology models for angiogenesis, extracellular matrix, and procollagen expression signaling.

Endogenous incretin peptide investigated for GLP-1 receptor activation and glucose-dependent insulin signaling.

Melanocortin receptor agonist (MC3R/MC4R) investigated for central nervous system pathway activation.

Small-molecule NNMT inhibitor investigated for nicotinamide N-methyltransferase blockade and NAD+ salvage pathway effects.

GHRH analog investigated for GHRH receptor (GHRHR) binding and somatotroph signaling kinetics.

Delta sleep-inducing peptide investigated for sleep-wake cycle modulation and stress response.

D-retro-inverso peptide investigated for disruption of the FOXO4–p53 interaction in cellular senescence models.

KISS1 gene product investigated for GnRH neuron activation and reproductive endocrine axis regulation.

Tuftsin analog investigated for anxiolytic-like activity via monoamine neurotransmitter and BDNF modulation.

hGH C-terminal fragment (177-191) investigated for adipocyte receptor signaling independent of the IGF-1 axis.

Non-selective melanocortin receptor agonist studied for MC1R-MC5R binding characteristics.

Terminally modified Semax analog investigated for neurotrophic signaling and increased metabolic stability.

Endogenous cyclic nonapeptide investigated for oxytocin receptor (OXTR) binding and neuroendocrine signaling.

Terminally modified Selank analog investigated for GABAergic modulation and increased metabolic stability.